Kelonia Therapeutics Presents Updated First-in-Human Data From Phase 1 inMMyCAR Study of KLN-1010 in Vivo BCMA CAR-T Therapy at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Key Takeaways

• 100% ORR with MRD‑negative responses in all evaluable patients
• Median 13‑day consent‑to‑infusion timeline, enabling outpatient treatment
• No lymphodepleting chemotherapy; CAR‑T cells persist longer than ex‑vivo therapies
• Grade 1‑2 CRS in 89% of patients; one Grade 3 ICANS event
• Eli Lilly acquisition pending, could accelerate KLN‑1010 commercialization

Pulse Analysis

Kelonia’s KLN‑1010 is generating buzz after ASCO 2026 revealed a perfect overall response rate in its first‑in‑human trial. The in‑vivo gene delivery platform creates anti‑BCMA CAR‑T cells directly inside patients, sidestepping the labor‑intensive ex‑vivo manufacturing that has limited CAR‑T availability. Early results show deep, MRD‑negative remissions that persist beyond ten months, with a safety profile comparable to existing CAR‑T products but delivered in an outpatient setting after just 13 days from consent to infusion. This streamlined approach could dramatically shorten treatment timelines and reduce costs for relapsed and refractory multiple myeloma.

The iGPS technology underpinning KLN‑1010 leverages a modified lentiviral vector to target bone‑marrow plasma cells, achieving robust expansion and long‑term persistence of CAR‑T cells without pre‑conditioning chemotherapy. Such a paradigm shift addresses two major barriers: the logistical bottleneck of cell manufacturing and the need for intensive hospital monitoring. By eliminating lymphodepletion, the therapy also reduces the risk of severe cytopenias and infections, making it more tolerable for heavily pre‑treated patients. Industry analysts see this as a potential catalyst for broader adoption of in‑vivo gene therapies across hematologic malignancies.

Strategically, Eli Lilly’s pending acquisition of Kelonia signals confidence that the company can integrate KLN‑1010 into its expansive oncology pipeline. If the deal closes, Lilly could leverage its global commercial infrastructure to accelerate regulatory filings and market rollout, positioning KLN‑1010 against established CAR‑T products like ide‑cabtagene vicleucel and ciltacabtagene autoleucel. The combination of high efficacy, outpatient convenience, and a fast‑track FDA designation may reshape competitive dynamics, prompting rivals to explore similar in‑vivo platforms. Investors are watching closely as Kelonia moves toward Phase 2, where larger cohorts will confirm whether the early promise translates into a scalable, market‑ready therapy.